N/A(healthy adults)
Conditions
Interventions
Oral intake of the test product (1 pill in a day
8 weeks)
Oral intake of the placebo product (1 pill in a day
Sponsors
TES Holdings Co., Ltd
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: [1]Females aged 35-49 years [2]Individuals who are healthy and have no chronic physical disease including skin disease [3]Individuals who are concerning on her dull skin [4]Individuals who are concerning on her blood circulation of the limbs [5]Individuals whose menstrual cycle is normal or health condition is stable after menopause [6]Individuals whose written informed consent has been obtained [7]Individuals who can have an examination in a designated day [8]Individuals judged appropriate for the study by the principal
Exclusion criteria
Exclusion criteria: [1]Individuals using medical products [2]Individuals with skin disease, such as atopic dermatitis [3]Individuals with strange skin conditions at measurement points [4]Individuals who used or applied a drug for treatment of disease in the past 1 month [5]Individuals who have a history of serious hepatopathy, kidney damage, heart disease, hematological and blood disease [6]Individuals who contract or have a history of serious gastrointestinal disease [7]Individuals with serious anemia [8]Individuals who are sensitive to test product or other foods, and medical products [9]Individuals who are or are possibly pregnant, or are lactating [10]Individuals who have an addiction to alcohol or a mental illness [11]Individuals who are a smoker [14]Individuals whose bowel habit is irregular [15]Individuals who are busy to their own work, housework or child care and neglect skin care [16]Individuals who cannot avoid daylight exposure during the test period [17]Individuals who had a habit to ingest health-promoting foods, foods for specified health uses, health foods, or supplements in the past 3 months or will ingest those foods during the test period [18]Individuals who have a habit to use drug claiming to improve skin condition in the past 3 months [19]Individuals who had been conducted an operation on the test spot [20]Individuals who participated in other clinical studies in the past 3 months [21]Individuals judged inappropriate for the study by the principal
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| [1]Colour difference (Week 0, Week 4, Week8) | — |
Secondary
| Measure | Time frame |
|---|---|
| *Secondary outcomes [1]Blood flow measurement with laser doppler (Week 0, Week 4, Week 8) [2]Observation for skin condition by a specialist (Week 0, Week 4, Week 8) *Safety [1]Diagnosis by doctors (Week 0, Week 4, Week 8) [2]Subject's diary(From the first day of ingestion of a test material to the last day of the test) *Other outcome Peeling of horny cell layer (Week 0, Week 4, Week 8) | — |
Countries
Japan
Contacts
Public ContactToshiyasu Tamura
TES Holdings Co., Ltd Department of Development for Clinical Trials
Outcome results
None listed